One of the biggest challenges facing patients and payers is the rising cost of specialty drugs including gene therapies and immunotherapies. These can have a huge impact on the bottom-line of payers unable to distribute risk across a large population. To increase efficiencies and control costs, stakeholders are considering new reimbursement and benefit designs for these products. The effect of these changes on access to medications, patient care, and the overall health care system are important considerations when evaluating reform proposals. Read the full article here.
(Source: AMCP Partnership Forum: What’s Next for Specialty Medication Benefit Design and Reimbursement. Journal of Managed Care & Specialty Pharmacy 2020 26:10, 1206-1213)